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METHODS: All studies were approved by our institution's Institutional Review Board and all patients gave informed consent. Patients received one of three dyes: EC17, ICG, or OTL38. Depending on the dye infused, patients were infused between 4 and 24 hours prior to surgery at doses ranging from 0.025 to 5 mg/kg. All tumors were imaged either in vivo and/or ex vivo. Fluorescence signal intensities of tumor and surrounding tissues were compared to compute tumor to background ratios (TBR), which were quantified using ImageJ. TBRs greater than 2 were considered positive for fluorescence.
RESULTS: Five patients had pathology proven thoracic RCC metastases, 4 pulmonary and 2 lymphatic (Table 1) . Metastases ranged in size from 1.1 to 3.9 cm. Two patients received EC17, two received ICG, and one received OTL38. Patients who received EC17 did not exhibit tumor fluorescence ex vivo. In patients receiving ICG and OTL38, pulmonary metastases had TBRs of 2.85 with ICG and 2.35 with OTL38. Lymphatic metastases had TBRs of 9.8 with ICG and 4.3 with OTL38.
CONCLUSIONS: Patients infused with dyes fluorescing in the NIR exhibited strong fluorescent signals in pulmonary and lymphatic thoracic metastases. The strongest fluorescent signals were present in lymphatic metastases, though this was not related to distance from the pleural surface. This preliminary data suggests IMI can serve as an effective adjunct to the surgeon in identifying thoracic RCC metastases. Future studies to assess the role of IMI in identifying RCC metastases in other locations are warranted. 
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PRESURGICAL TREATMENT WITH PAZOPANIB IMPROVED SURGICAL OUTCOME OF ADVANCED RENAL CELL CARCINOMA WITH INFERIOR VENA CAVA TUMOR THROMBUS Yasuyoshi Okamura*, Mariko Sakamoto, Yukari Bando, Kotaro Suzuki, Takuto Hara, Tomoaki Terakawa, Jyunya Furukawa, Kenichi Harada, Nobuykuki Hinata, Yuzo Nakano, Masato Fujisawa, Kobe, Japan INTRODUCTION AND OBJECTIVES: Previous studies reported that presurgical treatment with molecular targeted drug reduced operation risk by downsizing of tumor thrombus in patients with advanced renal cell carcinoma (RCC) with inferior vena cava tumor thrombus. We evaluated improvement of surgical outcome of resection both tumor and thrombus.
METHODS: A retrospective chart review of 42 patients who was operated for advanced RCC with inferior vena cava tumor thrombus at Kobe University Hospital from March 2008 to September 2018 was performed. We investigated surgical outcome of patients who received presurgical treatment by compared with surgery alone. We used pazopanib for presurgical treatment and MAYO classification for decision of tumor thrombus level.
RESULTS: Six patients received presurgical treatment before surgery and remaining 36 patients were treated with surgery alone. In presugical group there were 3 patients with level 3 thrombus and 3 patients with level 4 thrombus. In surgery alone group there were 12 patients with level 1 thrombus, 14 with level 2, 5 with level 3, 5 with level 4. In presurgical treatment group 4 patients showed reduction of tumor thrombus, of which 2 patients could avoid thoracic cavity approach and extracorporeal circulation. The average operation time were 500 min in presurgical group and 454 min in surgery alone group (P[0.51). the average blood loss were 1600 ml in presurgical group and 3192ml in surgery alone group (P[0.38). the average postoperative hospitalization were 13.2 days in presurgical group and 18.8 days in surgery alone group (P[0.02).In patients with level 3 and 4 thrombus in surgery alone group, the average operation time and blood loss were 627 min(presurgical 500 min, P[0.12 ) and 7393ml (presurgical 1600ml, P[0.04). Perioperative complications were observed in 33% of patients in both groups CONCLUSIONS: Presurgical treatment with pazopanib was able to ease surgery for advanced renal cell carcinoma with inferior vena cava tumor thrombus and improved surgical outcome with respect to blood loss and postoperative hospitalization. METHODS: We collected complete patient, treatment and outcome data of 262 mRCC patients from our institutional tertiary care center database. All patients were treated with TKI as single or multimodal treatment approach. Patients were stratified according to sRCC histology. Descriptive statistics as well as uni-and multivariable outcome metrics including progression-free (PFS) and overall survival (OS) were performed.
RESULTS: The entire cohort had a median age of 62 yrs. and 193 patients were male (74%). Overall, 18 (6.9%) pts. had sRCC variant histology. Of these, 15 (83.3%), 1 (5.6%) and 2 (11.2%) had clear cell, papillary or mixed baseline histology, respectively. Patients with sRCC differentiation had more frequently advanced disease stages >/[pT3 (p[0.011) and received more often cytoreductive surgery (p<0.001). There were no other differences in baseline characteristics. Most common first line TKIs in the entire cohort were Sunitinib (65.6%), Sorafenib (19.5%) and Pazopanib (10.3%), respectively. sRCC pts. received most commonly Sutinib (72.2%) for 1st line treatment. There was no difference in the number of therapy lines between sRCC and non-sRCC pts. At a mean follow-up of 32 months, Kaplan-Meier estimates demonstrated a significant reduced median PFS (3.7 vs 13.2 months, p[0.002) and OS (7.6 vs 29.0 months, p[0.001) in sRCC compared to non-sRCC pts. In multivariable analyses that adjusted for standard mRCC outcome prognosticators, sRCC was an independent predictor for inferior PFS (HR[ 2.51; CI: 1. p[0.039) and OS (HR[ 2.51; p[0.020) , respectively. In subgroup analyses of only sRCC pts., there was no difference in PFS or OS according to the administered drug in 1st or 2nd line therapy. Vol. 201, No. 4S, Supplement, Saturday, May 4, 2019 THE JOURNAL OF UROLOGY Ò e343
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